- Report
- October 2025
- 25 Pages
Poland
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 22 Pages
Finland
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 22 Pages
Guatemala
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 22 Pages
Croatia
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 22 Pages
Lithuania
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 21 Pages
Costa Rica
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 23 Pages
Kazakhstan
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 21 Pages
Pakistan
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 22 Pages
Serbia
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 19 Pages
Egypt
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 20 Pages
Finland
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 21 Pages
Croatia
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 22 Pages
Egypt
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 21 Pages
Guatemala
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 20 Pages
Costa Rica
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 22 Pages
Finland
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 22 Pages
Kazakhstan
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 21 Pages
Lithuania
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 21 Pages
Serbia
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 20 Pages
Pakistan
From €995EUR$1,181USD£890GBP

The Drugs by Therapeutic Area market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs for specific medical conditions. These drugs are designed to treat a wide range of diseases, from cancer to mental health disorders. Companies in this market typically specialize in one or more therapeutic areas, such as oncology, neurology, or cardiology. They develop drugs that target specific medical conditions and then market them to healthcare providers and patients. Companies in this market include Pfizer, Merck, Novartis, GlaxoSmithKline, and Sanofi. Show Less Read more